AR054232A1 - Derivados de piridina -2- carboxamida como antagonistas de mglur5 - Google Patents

Derivados de piridina -2- carboxamida como antagonistas de mglur5

Info

Publication number
AR054232A1
AR054232A1 AR20060100778A ARP060100778A AR054232A1 AR 054232 A1 AR054232 A1 AR 054232A1 AR 20060100778 A AR20060100778 A AR 20060100778A AR P060100778 A ARP060100778 A AR P060100778A AR 054232 A1 AR054232 A1 AR 054232A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
chf2
alkenyl
heteroaryl
Prior art date
Application number
AR20060100778A
Other languages
English (en)
Inventor
Georg Jaescnke
Sabine Kolczewski
Richard Hugh Phillip Porter
Eric Vieira
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36524927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054232(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR054232A1 publication Critical patent/AR054232A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Procesos de preparacion. Composiciones farmacéuticas, y uso de los mismos para la preparacion de los medicamentos utiles para tratar los trastornos del SNC. Reivindicacion 1. Los compuestos de la formula general (1) en la cual R1 es u anillo de 5- o 6- miembros respectivamente de las formulas (2) y (3); R2 es H, C1-7 alquilo, C3-6 cicloalquilo-(CH2)m-Ra; R3 es arilo o heteroarilo que son opcionalmente sustituidos por: CN, Cl, F, Br, CF3, CHF2, o -O-C1-7 alquilo, -(CO)-Rb, -(CH2)m-Rc, -NH-(CO)- C1-7 alquilo; -O-CH2F, -O-CHF2, -O-CF3, -S(O)2-Rd, C3-6 cicloalquilo heteroarilo que es opcionalmente sustituido por C1-7 alquilo; R4 es H, -OH, Cl. F, Br, CN, -CHF2, CF3, C1-7 alquilo, -O-(CO)-C1-7 alquilo, C3-6 cicloalquilo, o -(CH2)m-Re; R5 es C1- 7 alquilo o C1-7 alquil-C3-6 cicloalquilo; -(CH2)n-O-Rf, C3-8 alquenil-O-Rf, -(CH2)n-NRgRh; -C2-6alquenil-NRgRh o -(CH2)n-Re; Ra es -O-C1-7 alquilo o -OH; Rb es C1-7 alquilo, NH2, o -O-C1-7 alquilo; Rc es -OH, NH2, o NH-(CO)-O-C1-7 alquilo; Rd es C1- 7 alquilo, -NH2, -NH-C1-7 alquilo o -N-di(C1-7 alquil); Re es -OH, -CH2F, -CHF2, -CF3 o -O-(CO)-C1-7 alquilo; Rf es C1-7 alquilo, C3-8 alquenilo, C3-6 cicloalquilo, fenilo, bencilo o -(CO)-R'; Rg, Rh son, independientemente, H, c1-7 alquilo, C3-6 cicloalquilo, C3-8 alquenilo, fenilo, bencilo, o -(CO)-R' o Rg y Rh también, junto con el átomo de N al que están unidos, pueden formar un anillo heteroarilo o heterocíclico de 5- hasta 7- miembros que opcionalmente se pueden sustituir con 1 o 2 OH; R' es NH2, -NH-C1-7 alquilo, C1-7 alquilo o C1-7 alcoxi; m es 1 a 4; n es 2 a 6; p es 3 a 8; así como sus sales aceptables farmacéuticamente.
AR20060100778A 2005-03-04 2006-03-02 Derivados de piridina -2- carboxamida como antagonistas de mglur5 AR054232A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05101701 2005-03-04

Publications (1)

Publication Number Publication Date
AR054232A1 true AR054232A1 (es) 2007-06-13

Family

ID=36524927

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060100778A AR054232A1 (es) 2005-03-04 2006-03-02 Derivados de piridina -2- carboxamida como antagonistas de mglur5

Country Status (17)

Country Link
US (2) US7414060B2 (es)
EP (1) EP1858854B1 (es)
JP (1) JP4767975B2 (es)
KR (1) KR100929942B1 (es)
CN (1) CN101133027B (es)
AR (1) AR054232A1 (es)
AU (1) AU2006222289A1 (es)
BR (1) BRPI0607583A2 (es)
CA (1) CA2599974C (es)
ES (1) ES2476840T3 (es)
IL (1) IL185326A0 (es)
MX (1) MX2007010414A (es)
NO (1) NO20074258L (es)
RU (1) RU2411237C2 (es)
TW (1) TW200700391A (es)
WO (1) WO2006094639A1 (es)
ZA (1) ZA200707141B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0607583A2 (pt) * 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
US20060199828A1 (en) * 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
EP1966144A1 (en) * 2005-12-20 2008-09-10 Novartis AG Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
CN101854935A (zh) * 2007-10-12 2010-10-06 诺瓦提斯公司 用于治疗帕金森氏病的代谢型谷氨酸受体调节剂
WO2009047303A2 (en) * 2007-10-12 2009-04-16 Novartis Ag Metabotropic glutamate receptor modulators for the treatment of pervasive developmental disorder
WO2009078432A1 (ja) * 2007-12-18 2009-06-25 Taisho Pharmaceutical Co., Ltd. 1-アルキル-4-アミノ-1h-ピラゾール-3-カルボキサミド化合物
WO2010100050A1 (en) * 2009-03-05 2010-09-10 F. Hoffmann-La Roche Ag Pyridine-2-yl-carboxylic acid amides
US8501757B2 (en) * 2009-09-17 2013-08-06 Vanderbilt University Substituted phenylamine carboxamide analogs as mGluR5 negative allosteric modulators and methods of making and using the same
EP2490529A4 (en) * 2009-10-22 2013-08-28 Univ Vanderbilt ALLOSTERIC POTENTIALIZERS OF MGLUR4, COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DYSFUNCTION
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives
AU2014201036B2 (en) * 2010-04-06 2015-07-16 Nippon Soda Co., Ltd Nitrogen-containing heterocyclic compound and method for producing same
BR112012025242B1 (pt) * 2010-04-06 2018-04-17 Nippon Soda Co., Ltd. Método para produção de um derivado de amino-6- metilpiridino-n-óxido substituído
US8703768B2 (en) * 2010-06-09 2014-04-22 Hoffmann-La Roche Inc. Nitrogen containing heteroaryl compounds
AU2014353150A1 (en) 2013-11-19 2016-07-07 Vanderbilt University Substituted imidazopyridine and triazolopyridine compounds as negative allosteric modulators of mGluR5
US9533982B2 (en) 2014-03-20 2017-01-03 Vanderbilt University Substituted bicyclic heteroaryl carboxamide analogs as mGluR5 negative allosteric modulators
US9550778B2 (en) 2014-10-03 2017-01-24 Vanderbilt University Substituted 6-aryl-imidazopyridine and 6-aryl-triazolopyridine carboxamide analogs as negative allosteric modulators of mGluR5
WO2019169135A1 (en) 2018-02-28 2019-09-06 University Of Southern California Compositions and methods for modulating inflammatory and degenerative disorder
CN112624968B (zh) * 2021-01-18 2022-03-08 阿里生物新材料(常州)有限公司 一种5-氨基-3-氰基吡啶甲酸甲酯盐酸盐的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
GB9823871D0 (en) * 1998-10-30 1998-12-23 Pharmacia & Upjohn Spa 2-Amino-thiazole derivatives, process for their preparation, and their use as antitumour agents
WO2000073283A1 (en) * 1999-06-02 2000-12-07 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US7517517B2 (en) * 2002-03-29 2009-04-14 Janssen Pharmaceutica N.V. Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands
NZ540791A (en) 2003-02-13 2009-09-25 Banyu Pharma Co Ltd Novel 2-pyridinecarboxamide derivatives
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
AU2004226450A1 (en) * 2003-03-26 2004-10-14 Merck & Co. Inc. Benzamide modulators of metabotropic glutamate receptors
AU2005215379A1 (en) * 2004-02-12 2005-09-01 Merck & Co., Inc. Bipyridyl amides as modulators of metabotropic glutamate receptor-5
BRPI0607583A2 (pt) * 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos

Also Published As

Publication number Publication date
TW200700391A (en) 2007-01-01
KR20070107102A (ko) 2007-11-06
US7414060B2 (en) 2008-08-19
CA2599974A1 (en) 2006-09-14
US20080269256A1 (en) 2008-10-30
JP2008531618A (ja) 2008-08-14
MX2007010414A (es) 2007-09-25
AU2006222289A1 (en) 2006-09-14
CN101133027A (zh) 2008-02-27
EP1858854A1 (en) 2007-11-28
EP1858854B1 (en) 2014-05-07
ZA200707141B (en) 2008-10-29
JP4767975B2 (ja) 2011-09-07
RU2411237C2 (ru) 2011-02-10
NO20074258L (no) 2007-11-27
BRPI0607583A2 (pt) 2009-09-15
CA2599974C (en) 2013-12-31
RU2007132655A (ru) 2009-04-10
US20060199960A1 (en) 2006-09-07
CN101133027B (zh) 2011-03-30
IL185326A0 (en) 2008-02-09
WO2006094639A1 (en) 2006-09-14
ES2476840T3 (es) 2014-07-15
KR100929942B1 (ko) 2009-12-04

Similar Documents

Publication Publication Date Title
AR054232A1 (es) Derivados de piridina -2- carboxamida como antagonistas de mglur5
AR053153A1 (es) Derivados de pirazina -2- carboxamida como antagonistas de mglur5
AR059512A1 (es) Derivados de piridina -2- carboxamida
AR052558A1 (es) Derivados de tiazol-4-carboxamida como antagonistas de mglur5
AR072952A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR073136A1 (es) Compuestos de pirrol
ES2655391T3 (es) Inhibidores isoindolinona de fosfatidilinositol 3-quinasa
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
AR051995A1 (es) Derivados de tieno-piridina como intensificadores alostericos de gaba -b
AR078542A1 (es) Moduladores de gpr40 de pirrolidina
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
PE20090509A1 (es) El uso de derivados de benzamida para el tratamiento de transtornos del snc
AR052903A1 (es) Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a, composiciones farmaceuticas que los contienen y su empleo en el tratamiento de trastornos del sueno.
AR083849A1 (es) Antagonistas de mdm2 de espiro-oxindol
AR037355A1 (es) Compuesto derivado de difenilamina, composicion farmaceutica y su uso en la fabricacion de medicamentos
AR065280A1 (es) Agentes antiparasitarios
AR069796A1 (es) Derivados de bencimidazol, sustituido por carboxilo o por hidroxilo, proceso para prepararlos y composiciones farmaceuticas que los contienen
AR057408A1 (es) Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento
CO6220931A2 (es) Inhibidores de serina proteasas para el tratamiento de infecciones de vhc
RS53602B1 (en) 6,7-DIHIDRO-5H-IMIDASO [1,2-α] IMIDAZOL-3-CARBOXYLIC ACID DERIVATIVES
AR060604A1 (es) Nuevos arilamino n- heteroarilos como inhibidores de mek
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
AR084011A1 (es) Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal

Legal Events

Date Code Title Description
FA Abandonment or withdrawal